Dr. Patrick Soon-Shiong presented evidence at SITC
In both the triple negative breast cancer and head and neck squamous cell carcinoma trials patients had failed four to six lines of therapy. Three of eight experienced irPRs (- 70-100% reductions) and another three had irSD (two having shrinkage of between 21-49%).
In the metastatic pancreatic group all had failed at least three lines of therapy. Currently, less than 20% of patients goes on to receive third-line systemic therapy https://www.clinicaltherapeutics.com/article/S0149-2918(15)00154-X/fulltext Such patients have a median survival of 1-4 months. Nine out of ten treated had irSD (with three having shrinkage of between 6-27%). The median survival of the group is 9.5 months with a number continuing treatment.
Here is a link to the trials https://clinicaltrials.gov/ct2/results?term=QUILT&Search=Apply&recrs=b&recrs=a&age_v=&gndr=&type=&rslt=
This can be improved upon. For the two vaccines, it makes sense to target neoantigens as well as cancer stem cells. Then, using IL-15/TGFB instead of just IL-15 http://www.bloodjournal.org/content/126/23/3421 Also adding on RP-182 http://cancerres.aacrjournals.org/content/76/15_Supplement/PR03 (in some cases) NEO-201 http://cancerres.aacrjournals.org/content/77/13_Supplement/3025 https://www.frontiersin.org/articles/10.3389/fimmu.2017.01899/full and Nab-5404 http://cancerres.aacrjournals.org/content/69/2_Supplement/2138
All of the above are in the Nant pipeline.